April 17, 2018 / 6:06 PM / 8 months ago

BRIEF-FDA Approves Ultragenyx Pharmaceutical's Crysvita To Treat An Inherited Form Of Rickets

April 17 (Reuters) - U.S. Food and Drug Administration:

* U.S. FDA SAYS APPROVED CRYSVITA (BUROSUMAB) TO TREAT ADULTS & CHILDREN AGES 1 YEAR & OLDER WITH X-LINKED HYPOPHOSPHATEMIA, AN INHERITED FORM OF RICKETS

* U.S. FDA SAYS GRANTED APPROVAL OF CRYSVITA TO ULTRAGENYX PHARMACEUTICAL INC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below